Mechanistic Understanding Gaps Fundamental aspects of combination pharmacology require clarification[23]: Receptor-level interactions between components unknown (synergistic, additive, or antagonistic) Optimal dosing sequences and escalation protocols not scientifically established Tissue-specific distribution of combined formulation requires investigation Metabolic pathway interactions between incretin and amylin systems incompletely mapped Whether combination provides true synergy or simply additive effects remains unclear Population-Specific Considerations Research gaps exist for specific populations[24]: Renal impairment effects on peptide clearance inadequately studied Hepatic dysfunction impact on safety profile unclear Elderly populations (over 75 years) underrepresented in trials Racial and ethnic diversity in study populations limited Patients with cardiovascular disease require additional safety data Regulatory & Competitive Sport Status FDA Position Neither component has received FDA approval for any indication as of September 2025: GLP3 in phase 3 development for obesity and type 2 diabetes (TRIUMPH trials ongoing) Cagrilintide in phase 3 development as part of CagriSema combination Combined GLP3 + cagrilintide formulation not under regulatory review Not legally available for medical use, compounding, or human consumption No established therapeutic use basis for the combination Both peptides remain investigational drugs under active clinical development by their respective manufacturers
That infrastructure exists because the community learned through documented failures, wasted research material, and contamination events that trust without verification is not a quality system
BPC stands for Body Protection Compound, the name given to the parent gastric protein from which the peptide was derived in early-1990s research
The BBB disruption is associated with leakage of blood-derived proteins, including IgG, thrombin, hemoglobin, hemosiderin, and fibrinogen into the parenchyma, and increased IgG, albumin, and complement protein C3a levels in the CSF of ALS patients [46, 240]
